Chronic kidney disease

What is the study about?

The EASi-KIDNEY study is testing whether a new medication, currently called BI 690517, can help slow down the progression of kidney disease or reduce the risk of heart disease. The medication is being tested in combination with an existing, well-known treatment called empagliflozin.

Who can take part?

• Have chronic kidney disease but are not on dialysis

• Have moderate kidney function (not severely reduced)

• Are 18 years or older

• Do not have high levels of potassium in your blood

• Are able to start treatment with empagliflozin

What is involved?

If you join the study, you will:

• Attend five clinic visits in the first six months

• After that, visit the clinic once every six months

• Meet with a trained researcher (usually a nurse) at each visit, who will:

  • Ask questions about your health

  • Give you your supply of study medication

The study lasts for about three to four years. This is necessary to properly assess whether the new medication can make a real difference in slowing kidney disease, which typically progresses over a long period of time.

How do I take part?

If you are a kidney patient at our hospital and meet the criteria, we will contact you by letter with more information.